Business Context and Reporting Period
This Form 8-K is a current report filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) on June 20, 2013. The filing details corporate governance changes, including the appointment of an officer, the grant of equity options, and amendments to the company's Bylaws and Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance.
Material Changes
- Officer Appointment and Compensation: Allen Dodge was appointed as Secretary of the Company. In connection with this appointment, the Board granted him 10,000 stock options under the 2011 Equity Incentive Plan. The options vest immediately, have an exercise price of $3.00 per share, and expire five years from the grant date.
- Bylaw Amendment: The Board amended the Bylaws to permit shareholders to take action without a meeting, repealing the previous requirement that all shareholder actions occur at a meeting.
- Certificate of Incorporation Amendments:
- Increased authorized Preferred Stock from 3,000,000 to 4,500,000 shares.
- Granted the Board authority to create and designate preferences for future series of preferred stock.
- Clarified that converted preferred shares return to the authorized unissued pool and may not be reissued as the same series.
- New Preferred Stock Series: The Board designated a new Series D Preferred Stock, authorizing 1,500,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that the unregistered options were granted under exemptions from registration (Section 4(a)(5), 4(a)(2), and Rule 506) and that the recipient was an accredited investor. The securities may not be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the correct registrant name is Heatwurx, Inc., not Processa Pharmaceuticals, Inc.
- Confirm the impact of the new Series D Preferred Stock on existing shareholder dilution and voting rights.
- Review the specific terms of the Series D Preferred Stock designation filed as Exhibit 3.2.
- Check the total number of authorized shares post-amendment (4,500,000 Preferred) against current outstanding levels.